Clopidogrel Bisulfate
Product Images NDC 53808-1002

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 53808-1002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image For 75mg (Clopidogrel 75mg)

Label for Clopidogrel bisulfate 75 mg tablets, quantity 30. The label includes lot number and expiration date information, indicating it is prescription only. The packaging is by DOH Central Pharmacy in Tallahassee, FL, with a UPC barcode visible.*

FDA Label Image

Figure1 (Figure1)

A horizontal bar chart depicting the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite area under the curve (AUC) for Clopidogrel bisulfate. It shows mean values and 90% confidence intervals for dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, and omeprazole 80 mg, with AUC values ranging approximately from 0.4 to 1.4 on the x-axis.*

FDA Label Image

Figure2 (Figure2)

A line graph showing cumulative event rates (%) over 12 months of follow-up for two groups: Placebo plus aspirin and Clopidogrel plus aspirin. The Placebo group shows a higher cumulative event rate compared to the Clopidogrel group. The graph includes a p-value (0.00009) and notes that other standard therapies were used as appropriate.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart depicting the percent events and hazard ratios comparing Clopidogrel bisulfate (with aspirin) to placebo (with aspirin) across various baseline characteristics and concomitant medication therapies. The chart includes data categories like age, gender, race, diabetes status, previous medical conditions, and concurrent medications such as beta-blockers and ACE inhibitors. Each category shows risk estimates with confidence intervals, indicating relative event rates and treatment effects.*

FDA Label Image

Figure4 (Figure4)

A Kaplan-Meier survival curve graph showing the percent dead before first discharge over days since randomization (up to 28 days). The graph compares deaths in patients treated with Clopidogrel bisulfate versus placebo, indicating a proportional risk reduction with Clopidogrel bisulfate.*

FDA Label Image

Figure5 (Figure5)

A Kaplan-Meier survival curve plot showing the percentage of patients with death, reinfarction, or stroke before final discharge over days since randomization (up to 28 days). The chart compares two groups: placebo versus Clopidogrel bisulfate, indicating a lower event rate in the Clopidogrel group with a reported 28% proportional risk reduction.*

FDA Label Image

Figure6 (Figure6)

A forest plot chart showing odds ratios and confidence intervals comparing Clopidogrel and placebo based on various baseline categorizations such as sex, age, hours since onset, systolic blood pressure, heart rate, fibrinolytic agent given, prognostic index, and metoprolol allocation. The chart includes event percentages for Clopidogrel and placebo groups, with 99% and 95% confidence intervals, and a global heterogeneity test result.*

FDA Label Image

Figure7 (Figure7)

A forest plot chart comparing events (%) for Clopidogrel and Placebo across categories such as Killip class, Previous MI, and Infarct location. It shows odds ratios with confidence intervals, heterogeneity statistics, and a note indicating a proportional reduction of 9% with Clopidogrel. The chart visually displays the overall event rates and statistical comparisons between Clopidogrel and Placebo groups.*

FDA Label Image

Figure8 (Figure8)

A line graph comparing cumulative event rates (%) for fatal or non-fatal vascular events over 36 months of follow-up for Clopidogrel bisulfate and Aspirin. The x-axis represents months of follow-up, and the y-axis shows cumulative event rate. The graph indicates statistical significance with a P-value of 0.045.*

FDA Label Image

Structure (Structure)

Chemical structure of clopidogrel bisulfate showing its molecular framework with the bisulfate component indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.